Li Shuangxi, Ying Xiangji, Shan Fei, Jia Yongning, Li Zhemin, Xue Kan, Miao Rulin, Wang Yinkui, Bu Zhaode, Su Xiangqian, Li Ziyu, Ji Jiafu
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Chin J Cancer Res. 2022 Aug 30;34(4):406-414. doi: 10.21147/j.issn.1000-9604.2022.04.08.
This study aims to verify the feasibility and efficacy of laparoscopic lower mediastinal lymphadenectomy for Siewert type II/III adenocarcinoma of esophagogastric junction (AEG).
An exploratory, observational, prospective, cohort study will be carried out under the Idea, Development, Exploration, Assessment and Long-term Follow-up (IDEAL) framework (stage 2b).
The study will recruit 1,036 patients with cases of locally advanced AEG (Siewert type II/III, clinical stage cT2-4aN0-3M0), and 518 will be assigned to either the laparoscopy group or the open group.
Patients will receive lower mediastinal lymphadenectomy along with either total or proximal gastrectomy.
The primary endpoint is the number of lower mediastinal lymph nodes retrieved, and the secondary endpoints are the surgical safety and prognosis, including intraoperative and postoperative lower-mediastinal-lymphadenectomy-related morbidity and mortality, rate of rehospitalization, R0 resection rate, 3-year local recurrence rate, and 3-year overall survival.
The study will provide data for the guidance and development of surgical treatment strategies for AEG.
The study has been registered in ClinicalTrials.gov (No. NCT04443478).
本研究旨在验证腹腔镜下纵隔下淋巴结清扫术治疗食管胃交界部(AEG)Siewert II/III型腺癌的可行性和疗效。
将在理念、开发、探索、评估和长期随访(IDEAL)框架(2b期)下开展一项探索性、观察性、前瞻性队列研究。
本研究将招募1036例局部晚期AEG患者(Siewert II/III型,临床分期cT2-4aN0-3M0),其中518例将被分配至腹腔镜组或开放手术组。
患者将接受纵隔下淋巴结清扫术及全胃或近端胃切除术。
主要终点是纵隔下淋巴结的获取数量,次要终点是手术安全性和预后,包括术中及术后与纵隔下淋巴结清扫术相关的发病率和死亡率、再入院率、R0切除率、3年局部复发率和3年总生存率。
本研究将为AEG手术治疗策略的指导和发展提供数据。
本研究已在ClinicalTrials.gov注册(编号:NCT04443478)。